https://www.prnewswire.com/news-releases/acepodia-announces-nobel-laureate-carolyn-bertozzi-phd-as-chief-scientific-advisor-301925960.html
Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor
Sep 18, 2023 - /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and...
acepodia announcesnobel laureatecarolyn bertozziphchief
https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831-in-igg4-related-disease-302306506.html
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE1831 in...
Nov 15, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation...
announces fda clearanceinvestigational newacepodiadrugapplication
https://www.prnewswire.com/news-releases/acepodia-enters-strategic-clinical-collaboration-with-pfizer-to-accelerate-development-of-antibody-cell-conjugation-based-cell-therapies-in-autoimmune-diseases-302236377.html
Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of...
Sep 3, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation...
enters strategicacepodiaclinicalcollaborationpfizer
https://www.prnewswire.com/news-releases/acepodia-secures-100-million-series-d-financing-to-advance-301842681.html
Acepodia Secures $100 Million Series D Financing to Advance First-in-Class Cell Therapies with...
Jun 6, 2023 - /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and...
million seriescell therapiesacepodiasecuresfinancing
https://www.prnewswire.com/news-releases/acepodia-announces-preliminary-clinical-data-from-phase-1-clinical-trial-of-ace1831-first-ever-anti-cd20-antibody-conjugated-allogenic-gamma-delta-t-cell-therapy-for-non-hodgkins-lymphoma-302139302.html
Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever...
May 8, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation...
acepodia announcesclinical datapreliminaryphasetrial
https://www.biotechtv.com/post/acepodia-april-3-2024
Nobel laureate Carolyn Bertozzi and Acepodia Co-Founder Sonny Hsiao on the science of antibody-cell...
Apr 3, 2024 - Dr. Bertozzi and Dr. Hsiao describe how Acepodia is leveraging biorthogonal chemistry to conjugate antibodies to allogeneic γδ2 T cells as a treatment for...
nobel laureatecarolyn bertozzico founderacepodiasonny
https://www.prnewswire.com/news-releases/acepodia-presents-preclinical-data-on-antibody-dual-drugs-conjugation-ad2c-technology-at-aacr-annual-meeting-2025-302433216.html
Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR...
Apr 21, 2025 - /PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug...
preclinical dataacepodiapresentsantibodydual
https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace2016-a-first-in-class-allogeneic-anti-egfr-cell-therapy-302052466.html
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a...
Feb 4, 2024 - /PRNewswire/ -- Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation...
announces fda clearanceinvestigational newacepodiadrugapplication
https://www.acepodia.com/newsroom-detail/Carolyn_Bertozzi_Board_of_Directors/
Acepodia Appoints Nobel Laureate Dr. Carolyn Bertozzi to Its Board of Directors-Acepodia® |...
nobel laureatedr carolynacepodiaappointsbertozzi
https://www.acepodia.com/newsroom-detail/acepodia_announces_Emerging_Stock_Listing_Taipei_Exchange/
Acepodia Announces Emerging Stock Listing on The Taipei Exchange-Acepodia® | POWERFUL, ACCESSIBLE...
acepodia announcesemergingstocklistingtaipei
https://www.acepodia.com/about/
Acepodia is pioneering next-generation cell therapy.
Acepodia is developing first-in-class, off-the-shelf allogeneic cell therapies with significantly improved potency, better safety and broad applicability...
next generationacepodiapioneeringcelltherapy
https://www.acepodia.com/newsroom-detail/acepodia_board_announcement_eng/
Acepodia Announced CEO Dr. Sonny Hsiao’s Appointment as Chairman and Extraordinary Shareholders’...
Acepodia (The Company, 6976:TT), a clinical-stage biotechnology company pioneering allogeneic cell therapies, announced today that its current CEO, Dr. Sonny...
ceo dracepodiaannouncedsonnyappointment
https://www.acepodia.com/tw/
Acepodia 育世博生物科技股份有限公司
Acepodia is developing innovative, highly effective cell therapies for cancer that are broadly accessible for patients.
acepodia
https://www.globenewswire.com/news-release/2021/12/02/2345016/0/en/Acepodia-Raises-109-Million-Series-C-Financing-to-Advance-Development-of-First-in-Class-Antibody-Cell-Effector-Therapies.html
Acepodia Raises $109 Million Series C Financing to Advance
Dec 2, 2021 - Visionary technology investor Samuel Chen to join Board of Directors...
million seriesacepodiaraisesfinancingadvance
https://www.prnewswire.com/news-releases/acepodia-to-present-preclinical-data-on-its-gamma-delta-t-cell-therapy-candidate-ace1831-at-2022-sitc-annual-meeting-301667249.html
Acepodia to Present Preclinical Data on its Gamma Delta T cell Therapy Candidate, ACE1831, at 2022...
Nov 3, 2022 - /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC)...
preclinical datacell therapyacepodiapresentgamma
https://www.prnewswire.com/news-releases/acepodia-announces-fda-clearance-of-ind-application-for-ace1831-an-anti-cd20-armed-allogeneic-gamma-delta-t-cell-therapy-candidate-to-treat-patients-with-non-hodgkins-lymphoma-301570711.html
Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic...
Jun 20, 2022 - /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC)...
announces fda clearanceacepodiaindapplicationanti
https://www.acepodia.com/newsroom-detail/acepodia_with_william_blair_fireside_chat_acep1831_preliminary_data/
William Blair Fireside chat with Acepodia-Acepodia® | POWERFUL, ACCESSIBLE CELL THERAPIES FOR...
william blairfireside chatcell therapiesacepodiapowerful
https://www.prnewswire.com/news-releases/acepodia-congratulates-laureates-of-the-2022-nobel-prize-in-chemistry-and-shares-the-excitement-to-translate-click-chemistry-into-a-new-class-of-investigational-therapies-301643409.html
Acepodia Congratulates Laureates of the 2022 Nobel Prize in Chemistry and Shares the Excitement to...
Oct 7, 2022 - /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC)...
nobel prizeacepodiacongratulateslaureateschemistry